Boston Scientific Corporation $BSX Shares Bought by NewEdge Wealth LLC

NewEdge Wealth LLC grew its position in Boston Scientific Corporation (NYSE:BSX) by 18.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 62,699 shares of the medical equipment provider’s stock after acquiring an additional 9,826 shares during the quarter. NewEdge Wealth LLC’s holdings in Boston Scientific were worth $6,201,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of BSX. Steph & Co. purchased a new stake in Boston Scientific in the 3rd quarter valued at $25,000. Financial Consulate Inc. acquired a new position in Boston Scientific in the third quarter valued at $25,000. Murphy & Mullick Capital Management Corp raised its holdings in shares of Boston Scientific by 200.0% in the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 170 shares during the last quarter. FWL Investment Management LLC acquired a new stake in shares of Boston Scientific during the second quarter worth about $26,000. Finally, United Community Bank grew its holdings in shares of Boston Scientific by 115.7% during the third quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 147 shares during the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Stock Performance

Shares of BSX opened at $75.81 on Friday. The company has a quick ratio of 0.96, a current ratio of 1.62 and a debt-to-equity ratio of 0.46. Boston Scientific Corporation has a 52-week low of $72.69 and a 52-week high of $109.50. The company has a 50-day simple moving average of $89.59 and a 200-day simple moving average of $96.85. The company has a market capitalization of $112.49 billion, a PE ratio of 39.08, a P/E/G ratio of 1.05 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The company had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. During the same period in the prior year, the business posted $0.70 earnings per share. The firm’s revenue for the quarter was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Equities research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Activity at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the sale, the executive vice president directly owned 23,600 shares in the company, valued at $2,396,580. The trade was a 42.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.50% of the company’s stock.

Analyst Upgrades and Downgrades

BSX has been the subject of a number of recent research reports. Morgan Stanley decreased their price objective on Boston Scientific from $130.00 to $118.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Wells Fargo & Company decreased their price target on Boston Scientific from $125.00 to $94.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. TD Cowen dropped their price objective on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a research note on Monday, February 2nd. Truist Financial reduced their target price on shares of Boston Scientific from $120.00 to $95.00 and set a “buy” rating for the company in a research note on Thursday, February 5th. Finally, UBS Group lowered their target price on shares of Boston Scientific from $140.00 to $120.00 and set a “buy” rating on the stock in a report on Thursday, February 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $108.36.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.